Corporate Presentation

Rare diseases CHI Opportunity to treat up to 800 patients with diffuse CHI at ultra-rare disease price levels in the US Patients eligible for dasiglucagon treatment in the US ZEAL& ZEALAND PHARMA Ultra-rare disease therapy analogues with clear clinical value command premium prices in US5 Annual treatment cost (k$) 700-800 Diffuse CHI patients 1,500 • ~60% of CHI patients are diagnosed with diffuse CHI1 ~45-70 newly diagnosed diffuse CHI patients/year 2,3,4 1,250 Naglazyme All diffuse CHI patients considered eligible for dasiglucagon treatment4 Kanuma 1,000 Procysbi Majority of patients are treated and closely followed by pediatric endocrinologists in few Centers of Excellence4 750 • Elaprase Focal CHI patients 500 400-500 Most focal patients are cured after pancreatic surgery, while few patients will require continued short- or longer-term medical treatment Aldurazyme Ultomiris 250 # of CHI patients 0 500 Diffuse CHI Focal CHI 1Arya et al. Plos One 2014;9:e98054; 2Arnoux JB et al. 2011 Orphanet J Rare Dis;6:63; 3Yau et al. Plos One 2020;15(2):4 Based on KOL interviews (2022); 5 Zealand Pharma Payer & Pricing Research, December 2022 Indications by product: Procysbi (nephropathic cystinosis); Naglazyme (Maratolamy syndrome); Ultomoris (atypical hemolytic uremic syndrome); Kanuma (lysosomal acid lipase deficiency); Luxturna (biallelic RPE65 mutation-associated retinal dystrophy); Elaprase (Hunter syndrome); Aldurazyme (Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I). Luxturna 1,000 1,500 Patient population 37

View entire presentation